Halothane hepatitis patients have serum antibodies that react with protein disulfide isomerase
Jackie L. Martin, J. Gerald Kenna, Brian M. Martin, David Thomassen, George F. Reed, Lance R. Pohl – 1 October 1993 – Clinical and laboratory evidence suggests that the fulminant liver failure sometimes associated with the inhalation anesthetic halothane may be an immunemediated toxicity. Most importantly, the vast majority of patients with a clinical diagnosis of halothane hepatitis have serum antibodies, which react with one or more specific liver microsomal proteins that have been covalently altered by the trifluoroacetyl chloride metabolite of halothane.